Dipartimento di Scienze Cliniche

Prof.ssa Claudia Balotta

Pubblicazioni nel quinquennio 2003-2007: 14

• S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, Baldanti F, Bagnarelli P, Clementi M. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS.2003 Mar28;17(5):663-71.
• Comandini U, Balotta C. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates. Scand J Infect Dis Suppl. 2003 Dec;35 Suppl 106:75-8. Review.M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS. 2004 Jan 23;18(2):227-35.
• CF, Cozzi-Lepri A, Forbici F, Bertoli A, Violin M, Stella Mura M, Cadeo G, Orani A, Chirianni A, De Stefano C, Balotta C, d'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis. 2004 Jun 1;189(11):1983-7. Epub 2004 May 12.
• Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS. 2004 Aug 20;18(12):F11-9.
• Luca A, Cozzi-Lepri A, Perno CF, Balotta C, Di Giambenedetto S, Poggio A, Pagano G, Tositti G, Piscopo R, Del Forno A, Chiodo F, Magnani G, d'Arminio Monforte A; ICoNA drug resistance study group; ICoNA study group. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antivir Ther. 2004 Oct;9(5):743-52.
• L, Brindicci G, Lo Caputo S, Punzi G, Scarabaggio T, Riva C, Di Bari C, Pierotti P, Saracino A, Lagioia A, Mazzotta F, Balotta C, Angarano G. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol. 2005 Apr;75(4):483-90.
• AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005 Sep 15;192(6):958-66. Epub 2005 Aug 15. Erratum in: J Infect Dis. 2005 Oct 15;192(8):1501.
• B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kucherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):505-11.
• D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K; CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006 Jan 2;20(1):21-8.
• de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr. 2006 Mar;41(3):352-60.
• S, Violin M, Romano L, Razzolini F, Vicenti I, Galli A, Duca P, Caramma I, Balotta C, Zazzi M. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther. 2006;11(3):329-34.
• M, Montieri S, Salemi M, De Oliveira T, Dorrucci M, Sinicco A, De Luca A, Giuliani M, Balotta C, Rezza G. An outbreak of HIV-1 subtype G among Italian injecting drug users. AIDS. 2007 May 31;21(9):1213-5.

Dr. Mario Corbellino

Pubblicazioni nel quinquennio 2003-2007: 9

• C, Scalamogna C, Calattini S, Poli F, Scalamogna M, Galli M, Moroni M, Corbellino M. KSHV reactivation in post-transplant Kaposi sarcoma. Nat Med. 2003 Aug;9(8):986.
• G, Stellari A, Lattuada A, Corbellino M, Parravicini C, Calzarossa C, Cenzuales S, Moroni M, Galli M, Rossi E. ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost. 2003 Nov;90(5):955-6.
• AL, Corbellino M, Tosca N, Capelletti A, Scalamogna C, Galli M, Parravicini C. Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma? AIDS. 2004 May 21;18(8):1224-6.
• P, Gianelli E, Calattini S, Corbellino M, Antinori S, Meroni L. Itraconazole can be effective in the treatment of sporotrichoid leishmaniasis. J Travel Med. 2004 Sep-Oct;11(5):328-30.
• S, Galimberti L, Gianelli E, Calattini S, Piazza M, Morelli P, Moroni M, Galli M, Corbellino M. Prospective observational study of fever in hospitalized returning travelers and migrants from tropical areas, 1997-2001. J Travel Med. 2004 May-Jun;11(3):135-42.
• S, Magni C, Nebuloni M, Parravicini C, Corbellino M, Sollima S, Galimberti L, Ridolfo AL, Wheat LJ. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine (Baltimore). 2006 Jan;85(1):22-36. Review.
• E, Tiribelli M, Battista M, Michelutti A, Corbellino M, Viale P, Fanin R, Damiani D. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol. 2006 May;81(5):355-7.
• S, Calattini S, Longhi E, Bestetti G, Piolini R, Magni C, Orlando G, Gramiccia M, Acquaviva V, Foschi A, Corvasce S, Colomba C, Titone L, Parravicini C, Cascio A, Corbellino M. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis. 2007 Jun 15;44(12):1602-10. Epub 2007 May 7. Review.
• E, Bestetti G, Acquaviva V, Foschi A, Piolini R, Meroni L, Magni C, Antinori S, Parravicini C, Corbellino M. Human parvovirus 4 in the bone marrow of Italian patients with AIDS. AIDS. 2007 Jul 11;21(11):1481-3.

Dott. Luca Meroni

Pubblicazioni nel quinquennio 2003-2007: 10

• Meroni L, Marchetti G, Gatti N, Monforte A, Galli M. Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):277-8.
• Galli M, Gervasoni C, Ridolfo AL, Trabattoni D, Santambrogio S, Vaccarezza M, Meroni L, Trifiro G, Moroni M, Norbiato G, Clerici M. Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. AIDS. 2003 Apr;17 Suppl 1:S155-61.
• Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, Moroni M, Clerici M, Gori A. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS. 2004 Jan 23;18(2):211-6.
• Marchetti G, Meroni L, Molteni C, Taskaris G, Gazzola L, Galli M, Clerici M, Moroni M, Franzetti F, Gori A.
• IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. Antivir Ther. 2004 Jun;9(3):447-52.
• Meroni L, Riva A, Morelli P, Galazzi M, Mologni D, Adorni F, Galli M. Increased CD36 expression on circulating monocytes during HIV infection. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):310-3.
• Meroni L, Giacomet V, Morelli P, Erba P, Galazzi M, Riva A, Vigano A, Galli M. Increased CD36 expression in vertically human immunodeficiency virus-infected children unrelated to antiretroviral therapy. Pediatr Infect Dis J. 2005 Jun;24(6):576-7.
• Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte A, Galli M, Meroni L. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS. 2006 Aug 22;20(13):1727-36.
• Pigatto PD, Meroni L. Risks of dental amalgam in children. JAMA. 2006 Sep 27;296(12):1461; author reply 1461.

Dott. Agostino Riva

Pubblicazioni nel quinquennio 2003-2007: 11

• Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C, Esposito R, Galli M. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther. 2003 Aug;8(4):315-21.
• Bongiovanni M, Chiesa E, Riva A, d'Arminio Monforte A, Bini T. Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir. Int J Antimicrob Agents. 2003 Dec;22(6):630-1.
• Milazzo L, Riva A, Sangaletti O, Piazza M, Antinori S, Moroni M. 13C-Methionine breath test detects liver mitochondrial impairment in HIV-infected patients with antiretroviral drug-related hyperlactatemia. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):429-32.
• Mazzucchelli R, Amadio M, Curreli S, Denaro F, Bemis K, Reid W, Bryant J, Riva A, Galli M, Zella D.
• Establishment of an ex vivo model of monocytes-derived macrophages differentiated from peripheral blood mononuclear cells (PBMCs) from HIV-1 transgenic rats. Mol Immunol. 2004 Aug;41(10):979-84.
• Milazzo L, Piazza M, Sangaletti O, Gatti N, Cappelletti A, Adorni F, Antinori S, Galli M, Moroni M, Riva A.
• 13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother. 2005 Jan;55(1):84-9. Epub 2004 Dec 8.
• Di Pierro E, Cappellini MD, Mazzucchelli R, Moriondo V, Mologni D, Zanone Poma B, Riva A. A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria. Exp Hematol. 2005 May;33(5):584-91.
• Milazzo L, Menzaghi B, Massetto B, Sangaletti O, Riva A. 13C-methionine breath test detects drug-related hepatic mitochondrial dysfunction in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):252-3; author reply 253-4.
• Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, Galli M, Moroni M, Clerici M, Riva A. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. Am J Gastroenterol. 2006 Feb;101(2):399-402.
• Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A; rHoPeS Group. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS. 2006 Feb 28;20(4):567-74.

Dr Stefano Rusconi

Pubblicazioni nel quinquennio 2003-2007: 26

• Bongiovanni M, Bini T, Tordato F, Cicconi P, Melzi S, Repetto D, Sollima S, Rusconi S, d'Arminio Monforte A. Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. J Antimicrob Chemother. 2003 Jan;51(1):171-4.
• Costa P, Rusconi S, Fogli M, Mavilio D, Murdaca G, Puppo F, Mingari MC, Galli M, Moretta L, De Maria A. Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients. AIDS. 2003 Jan 24;17(2):257-60.
• Rusconi S. Alovudine Medivir. Curr Opin Investig Drugs. 2003 Feb;4(2):219-23. Review.
• Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antivir Ther. 2003 Feb;8(1):27-35.
• Rusconi S. Tipranavir. Drugs. 2003;63(15):1619-20.
• Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther. 2003 Jun;8(3):209-14.
• Bulgheroni E, Croce F, Citterio P, Vigano O, Visona R, Sala E, Galli M, Rusconi S. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J Clin Virol. 2004 Jan;29(1):27-32.
• Baldanti F, Lilleri D, Campanini G, Comolli G, Ridolfo AL, Rusconi S, Gerna G. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J Antimicrob Chemother. 2004 Mar;53(3):536-9. Epub 2004 Jan 22.
• Bulgheroni E, Citterio P, Croce F, Lo Cicero M, Vigano O, Soster F, Chou TC, Galli M, Rusconi S. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J Antimicrob Chemother. 2004 Mar;53(3):464-8. Epub 2004 Feb 12.
• Rusconi S, Innocenti A, Vullo D, Mastrolorenzo A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7.
• Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. New advances in HIV entry inhibitors development. Curr Drug Targets Infect Disord. 2004 Dec;4(4):339-55. Review
• Vigano A, Schneider L, Giacomet V, Bianchi R, Cicero ML, Soster F, Bulgheroni E, Rusconi S. Efficacy and tolerability of multiple drug therapy in HIV-infected children. J Infect. 2005 Jun;50(5):404-11.
• Lo Cicero M, Bulgheroni E, Soster F, Vigano O, Cicconi P, Galli M, Rusconi S. Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):238-41.
• Bulgheroni E, Bandera A, Galli M, Gori A, Rusconi S. Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol. AIDS Res Hum Retroviruses. 2005 Sep;21(9):815-9.
• Vigano A, Trabattoni D, Schneider L, Ottaviani F, Aliffi A, Longhi E, Rusconi S, Clerici M. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr. 2006 Mar;148(3):389-91.
• Rusconi S. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, USA, 5-8 February 2005. J HIV Ther. 2006 Mar;11(1):20-2.
• Citterio P, Rusconi S. Novel inhibitors of the early steps of the HIV-1 life cycle. Expert Opin Investig Drugs. 2007 Jan;16(1):11-23. Review.
• Gervasoni C, Vigano O, Grinelli E, Ortu M, Galli M, Rusconi S. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. AIDS Patient Care STDS. 2007 Jan;21(1):1-3.
• Temperini C, Innocenti A, Guerri A, Scozzafava A, Rusconi S, Supuran CT. Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2210-5. Epub 2007 Feb 8.
• Rusconi S. Revisiting the concept of a genetic barrier to resistance. J HIV Ther. 2006 Dec;11(4):81-3. Review.
• Rusconi S. Conference Report: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 25-28 February 2007. J HIV Ther. 2007 Mar;12(1):36-8.
• Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr Top Med Chem. 2007;7(13):1273-89. Review.
• Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, Kraft M, Neubacher D, Sabo JP. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS. 2007 Sep 12;21(14):1977-80.
• Milazzo L, Menzaghi B, Corvasce S, Bonfanti P, Rusconi S, Ridolfo AL, Antinori S. Safety of Statin Therapy in HIV/Hepatitis C Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):258-260.

Dr. Gianni Zehender

Pubblicazioni nel quinquennio 2003-2007: 6

• Zehender G, De Maddalena C, Milazzo L, Piazza M, Galli M, Tanzi E, Bruno R. Hepatitis B virus genotype distribution in HIV-1 coinfected patients. Gastroenterology. 2003 Nov;125(5):1559-60.
• Zehender G, Colasante C, De Maddalena C, Bernini F, Savasi V, Persico T, Merli S, Ridolfo A, Santambrogio S, Moroni M, Galli M. High prevalence of human T-lymphotropic virus type 1 (HTLV-1) in immigrant male-to-female transsexual sex workers with HIV-1 infection. J Med Virol. 2004 Oct;74(2):207-15.
• Galli M, Bernini F, Zehender G. Alexander the Great and West Nile virus encephalitis. Emerg Infect Dis. 2004 Jul;10(7):1330-2.
• Zehender G, De Maddalena C, Bernini F, Ebranati E, Monti G, Pioltelli P, Galli M. Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol. 2005 Jul;79(14):9145-56.
• De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, Bernini F, Ebranati E, Cargnel A, Bruno R, Galli M, Zehender G. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology. 2007 Aug 15;365(1):113-24. Epub 2007 Apr 23.
• Zehender G, Ebranati E, Bernini F, De Maddalena C, Giambelli C, Collins J, Valverde A, Montin Z, Galli M. Phylogeny of human T cell lymphotropic virus type 1 in peru: a high degree of evolutionary relatedness with South african isolates. AIDS Res Hum Retroviruses. 2007 Sep;23(9):1146-9.